Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.47 Million USD | -3.03% |
| 2022 | 5.64 Million USD | -16.8% |
| 2021 | 6.79 Million USD | -12.79% |
| 2020 | 7.78 Million USD | -4.76% |
| 2019 | 8.17 Million USD | -5.95% |
| 2018 | 8.69 Million USD | -17.81% |
| 2017 | 10.57 Million USD | 24.7% |
| 2016 | 8.48 Million USD | 16.26% |
| 2015 | 7.29 Million USD | -24.37% |
| 2014 | 9.64 Million USD | 18.49% |
| 2013 | 8.14 Million USD | 6.36% |
| 2012 | 7.65 Million USD | 0.7% |
| 2011 | 7.6 Million USD | 55.14% |
| 2010 | 4.89 Million USD | 151.47% |
| 2009 | 1.94 Million USD | 140.01% |
| 2008 | 811.76 Thousand USD | 17939.27% |
| 2007 | 4500.00 USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.5 Million USD | 0.49% |
| 2023 Q4 | 5.47 Million USD | 3.81% |
| 2023 Q2 | 5.61 Million USD | -5.19% |
| 2023 Q1 | 5.91 Million USD | 4.74% |
| 2023 FY | 5.47 Million USD | -3.03% |
| 2023 Q3 | 5.27 Million USD | -5.94% |
| 2022 Q4 | 5.64 Million USD | -3.32% |
| 2022 Q1 | 6.43 Million USD | -5.26% |
| 2022 FY | 5.64 Million USD | -16.8% |
| 2022 Q2 | 6.12 Million USD | -4.82% |
| 2022 Q3 | 5.84 Million USD | -4.57% |
| 2021 Q4 | 6.79 Million USD | 1.06% |
| 2021 FY | 6.79 Million USD | -12.79% |
| 2021 Q2 | 8.97 Million USD | 27.77% |
| 2021 Q1 | 7.02 Million USD | -9.81% |
| 2021 Q3 | 6.71 Million USD | -25.11% |
| 2020 Q2 | 9.11 Million USD | 2.86% |
| 2020 Q4 | 7.78 Million USD | -8.18% |
| 2020 Q1 | 8.85 Million USD | 8.37% |
| 2020 Q3 | 8.48 Million USD | -6.94% |
| 2020 FY | 7.78 Million USD | -4.76% |
| 2019 Q4 | 8.17 Million USD | -1.42% |
| 2019 FY | 8.17 Million USD | -5.95% |
| 2019 Q3 | 8.29 Million USD | -4.05% |
| 2019 Q1 | 8.27 Million USD | -4.77% |
| 2019 Q2 | 8.64 Million USD | 4.42% |
| 2018 Q3 | 9.46 Million USD | -10.83% |
| 2018 Q2 | 10.61 Million USD | -1.93% |
| 2018 Q1 | 10.82 Million USD | 2.36% |
| 2018 FY | 8.69 Million USD | -17.81% |
| 2018 Q4 | 8.69 Million USD | -8.19% |
| 2017 Q1 | 8.77 Million USD | 3.44% |
| 2017 FY | 10.57 Million USD | 24.7% |
| 2017 Q4 | 10.57 Million USD | 13.37% |
| 2017 Q3 | 9.32 Million USD | 7.77% |
| 2017 Q2 | 8.65 Million USD | -1.33% |
| 2016 Q2 | 7.64 Million USD | 2.21% |
| 2016 Q4 | 8.48 Million USD | 0.62% |
| 2016 Q3 | 8.42 Million USD | 10.3% |
| 2016 FY | 8.48 Million USD | 16.26% |
| 2016 Q1 | 7.47 Million USD | 2.49% |
| 2015 Q2 | 7.73 Million USD | -2.96% |
| 2015 FY | 7.29 Million USD | -24.37% |
| 2015 Q4 | 7.29 Million USD | -0.18% |
| 2015 Q1 | 7.97 Million USD | -17.32% |
| 2015 Q3 | 7.3 Million USD | -5.57% |
| 2014 Q3 | 9.39 Million USD | 0.63% |
| 2014 Q2 | 9.33 Million USD | -0.87% |
| 2014 Q1 | 9.41 Million USD | 15.65% |
| 2014 Q4 | 9.64 Million USD | 2.72% |
| 2014 FY | 9.64 Million USD | 18.49% |
| 2013 Q2 | 8.19 Million USD | 4.88% |
| 2013 FY | 8.14 Million USD | 6.36% |
| 2013 Q3 | 8.16 Million USD | -0.34% |
| 2013 Q4 | 8.14 Million USD | -0.27% |
| 2013 Q1 | 7.8 Million USD | 2.03% |
| 2012 Q2 | 9.01 Million USD | 23.36% |
| 2012 FY | 7.65 Million USD | 0.7% |
| 2012 Q4 | 7.65 Million USD | 2.98% |
| 2012 Q3 | 7.43 Million USD | -17.51% |
| 2012 Q1 | 7.3 Million USD | -3.91% |
| 2011 Q2 | 6.11 Million USD | 7.32% |
| 2011 FY | 7.6 Million USD | 55.14% |
| 2011 Q1 | 5.7 Million USD | 16.38% |
| 2011 Q4 | 7.6 Million USD | 8.69% |
| 2011 Q3 | 6.99 Million USD | 14.28% |
| 2010 Q3 | 4.07 Million USD | 23.97% |
| 2010 FY | 4.89 Million USD | 151.47% |
| 2010 Q4 | 4.89 Million USD | 20.23% |
| 2010 Q2 | 3.28 Million USD | 34.49% |
| 2010 Q1 | 2.44 Million USD | 25.46% |
| 2009 Q1 | 986.44 Thousand USD | 21.52% |
| 2009 Q3 | 1.66 Million USD | 49.24% |
| 2009 Q2 | 1.11 Million USD | 13.29% |
| 2009 FY | 1.94 Million USD | 140.01% |
| 2009 Q4 | 1.94 Million USD | 16.82% |
| 2008 Q4 | 811.76 Thousand USD | 205.51% |
| 2008 Q3 | 265.7 Thousand USD | 256.67% |
| 2008 Q2 | 74.49 Thousand USD | 14799.2% |
| 2008 Q1 | 500.00 USD | -88.89% |
| 2008 FY | 811.76 Thousand USD | 17939.27% |
| 2007 Q4 | 4500.00 USD | 847.37% |
| 2007 FY | 4500.00 USD | 0.0% |
| 2007 Q2 | 475.00 USD | 0.0% |
| 2007 Q3 | 475.00 USD | 0.0% |
| 2007 Q1 | 475.00 USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.441% |
| Neon Bloom, Inc. | 1.22 Million USD | -346.741% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -577.305% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12156.13% |
| Qrons Inc. | 1.48 Million USD | -267.969% |
| Rebus Holdings, Inc. | 5.24 Million USD | -4.502% |
| Skye Bioscience, Inc. | 14.07 Million USD | 61.072% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.717% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -19868.651% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.688% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2623.801% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 42.129% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.723% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 42.83% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1199.434% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.053% |
| Intellipharmaceutics International Inc. | 12 Million USD | 54.383% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -42.233% |
| Mesoblast Limited | 188.44 Million USD | 97.093% |
| Marizyme, Inc. | 26.67 Million USD | 79.464% |
| Genus plc | 485 Million USD | 98.871% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 6.241% |
| Pharming Group N.V. | 244.07 Million USD | 97.756% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -172.52% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -117.698% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -44.158% |
| ContraFect Corporation | 32.53 Million USD | 83.161% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -176.484% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -43.117% |
| IMV Inc. | 37.93 Million USD | 85.559% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 53.49% |
| MultiCell Technologies, Inc. | 1617.67 USD | -338535.198% |
| ONE Bio Corp. | 27.49 Million USD | 80.077% |
| Accustem Sciences Inc. | 1.07 Million USD | -407.58% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.924% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -158.999% |
| Q BioMed Inc. | 8.13 Million USD | 32.644% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.395% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -6.451% |
| Biomind Labs Inc. | 1.49 Million USD | -265.538% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.386% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 39.417% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 70.234% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -282.045% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3755.167% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 4.661% |
| GB Sciences, Inc. | 5.41 Million USD | -1.116% |
| Alpha Cognition Inc. | 7.16 Million USD | 23.543% |
| HST Global, Inc. | 593.59 Thousand USD | -822.855% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -335.041% |
| Halberd Corporation | 728.71 Thousand USD | -651.73% |
| Enzolytics Inc. | 365.26 Million USD | 98.5% |
| Agentix Corp. | 2.51 Million USD | -118.199% |
| Resverlogix Corp. | 67.39 Million USD | 91.872% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -553.129% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.769% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -219.603% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 77.863% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 53.978% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -49.461% |
| AVAX Technologies, Inc. | 3.99 Million USD | -37.164% |
| Zenith Capital Corp. | 27.56 Thousand USD | -19770.144% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.587% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2195.373% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -46.694% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -704.601% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -102.018% |
| Kadimastem Ltd | 3.5 Million USD | -56.297% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8084.793% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.102% |
| BioStem Technologies, Inc. | 15.9 Million USD | 65.557% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1078.828% |
| LadRx Corporation | 2.2 Million USD | -148.94% |
| Cell Source, Inc. | 15.8 Million USD | 65.344% |
| Regen BioPharma, Inc. | 5.45 Million USD | -0.373% |
| Regen BioPharma, Inc. | 5.45 Million USD | -0.373% |
| NovAccess Global Inc. | 7.86 Million USD | 30.312% |
| Affymax, Inc. | 8.87 Million USD | 38.248% |
| Itoco Inc. | 1.65 Million USD | -231.367% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -167.016% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 9.44% |
| Mobile Lads Corp. | 1.31 Million USD | -317.055% |
| CytoDyn Inc. | 127.89 Million USD | 95.717% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -13005.577% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -249.724% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 50.404% |
| SYBLEU INC | 681.41 Thousand USD | -703.918% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 10.225% |
| International Stem Cell Corporation | 5.27 Million USD | -3.809% |
| Bioxytran, Inc. | 3.24 Million USD | -68.58% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -775.347% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -18.645% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 86.638% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 75.396% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -170.467% |
| Neutra Corp. | 973.52 Thousand USD | -462.695% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 81.12% |
| PureTech Health plc | 125.58 Million USD | 95.638% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -45.803% |
| IXICO plc | 1.9 Million USD | -188.271% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 73.316% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.698% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Cellectis S.A. | 249.36 Million USD | 97.803% |